were followed for episodes of conjunctivitis, pneumonia, and wheezing during their 1st year of life.
Infections during pregnancy are often transmitted to the infant at the time of delivery. [4] [5] [6] Rates of transmission vary from 50 to 75% of infants born to infected mothers. Previous studies in women of all childbearing ages have shown that the use of erythromycin during pregnancy diminishes C. trachomatis transmission to the infant and prevents complications such as conjunctivitis and pneumonia. 7 '* Adolescents are particularly at risk for poor compliance with prenatal care and medication administration and for reinfection with C. trachomat/S. [9] [10] [11] There are no studies that have examined the effectiveness of erythromycin during pregnancy in a purely adolescent population.
This prospective cohort study was Because cultures may be somewhat fastidious, infants were followed for symptoms that could be related to C. trachomatis infection. 13 In examining conjunctivitis, pneumonia, and wheezing in the 2 groups, we found no differences in risk between infants born to mothers who were C. trachomatis negative and those born to mothers treated during pregnancy for C. trachomatis. Although C. trachomatis may be implicated in 1/3 of infants with pneumonia, 22 we found no increase in risk for pneumonia between the infants born to infected and noninfected mothers. Although C. trachomatis conjunctivitis has been found as often as 51% of the time in young infants with conjunctivitis, 23 we found no increase in risk for conjunctivitis between infants born to infected and noninfected mothers.
Wheezing following C. trachomat# infection has been reported by several authors. [24] [25] [26] Chronic C. trachomatis infections in infants have also been reported, some lasting over 2 years. 27 No evidence of increased wheezing or chronic infection was found in infants in the group born to mothers treated for C. trachomatis. 
